Treatment of atopic dermatitis in pediatric practice: challenges and solutions

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

This article addresses topical anti-inflammatory therapy for atopic dermatitis, the most common inflammatory skin disease with an early onset of clinical manifestations, which is relevant to pediatric clinical practice. The chronic, relapsing course of atopic dermatitis requires ongoing treatment and symptom control, which poses challenges not only to the efficacy but also to the safety of prescribed medications. In this regard, it is shown that pimecrolimus cream 1% is a useful topical treatment option for pediatricians. It can be prescribed both during exacerbations and for long-term anti-relapse treatment, including in infancy and early childhood. The efficacy and safety of this drug, as well as its advantages over topical glucocorticosteroids, have been confirmed by clinical studies and many years of domestic and international practice, as reflected in this article.

This article examines topical anti-inflammatory therapy for atopic dermatitis (AD), the most common chronic inflammatory skin disease that manifests primarily in early childhood, which is relevant to pediatric clinical practice. The chronic, relapsing course of AD requires long-term symptom control, which presents the clinician with two key challenges: achieving sustained remission and minimizing the risks associated with prolonged use of topical medications. Particular attention is paid to balancing the efficacy and safety of therapy, including modern approaches to the use of corticosteroids and calcineurin inhibitors. Therefore, pimecrolimus cream 1% occupies an important place in the arsenal of topical therapy for atopic dermatitis (AD) in children. The drug can be used both for the relief of exacerbations and for long-term anti-relapse treatment, including in infancy and early childhood. Its efficacy and favorable safety profile compared to topical glucocorticosteroids (TGCS) are confirmed by clinical trial data and many years of experience in Russian and international practice.

About the authors

Inna A. Larkova

Federal Research Center for Nutrition, Biotechnology, and Food Safety

Author for correspondence.
Email: inna_larkova@mail.ru

Cand. Sci. (Med.), Senior Researcher, Department of Allergology and Diet Therapy

Russian Federation, Moscow

Vera A. Revyakina

Federal Research Center for Nutrition, Biotechnology, and Food Safety

Email: inna_larkova@mail.ru

Dr. Sci. (Med.), Professor, Head of the Allergology Department

Russian Federation, Moscow

References

  1. Клинические рекомендации. Атопический дерматит. Утверждены Минздравом РФ, 2024. [Clinical guidelines. Atopic dermatitis. Approved by the Ministry of Health of the Russian Federation, 2024. (In Russ.)]. URL: https://cr.minzdrav.gov.ru/view-cr/265_3
  2. Laughter M.R., Maymone M.B.C., Mashayekhi S., et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309. https://dx.doi.org/10.1111/bjd.19580
  3. Wollenberg A., Barbarot S., Bieber T., et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. JEADV. 2018;32(5):657–682. https://dx.doi.org/10.1111/jdv.14891
  4. Wollenberg A., Kinberger M., Arents B., et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. JEADV. 2022;36(11):1904–26. https://dx.doi.org/10.1111/jdv.18429
  5. Nakahara T., Kido-Nakahara M., Tsuji G., et al. Basics and recent advances in the pathophysiology of atopic dermatitis. J Dermatol. 2021;48(2):130–139. https://dx.doi.org/10.1111/1346-8138.15664
  6. Tsakok T., Marrs T., Mohsin M., et al. Does atopic dermatitis cause food allergy? A systematic review. J Allergy Clin Immunol. 2016;137(4):1071–1078. https://dx.doi.org/10.1016/j.jaci.2015.10.049
  7. Kage P., Zarnowski J., Simon J.C., et al. Atopic dermatitis and psychosocial comorbidities – what’s new? Allergol Select. 2020;4:86–96. https://dx.doi.org/10.5414/ALX02174E
  8. Tier H.L., Balogh E.A., Bashyam A.M., et al. Tolerability of and adherence to topical treatments in atopic dermatitis: a narrative review. Dermatol Ther (Heidelb) 2021;11(2):415–431. https://dx.doi.org/10.1007/s13555-021-00500-4
  9. Huang A., Cho C., Leung D.Y.M., et al. Atopic dermatitis: early treatment in children. Curr Treat Options Allergy. 2017;4(3):355–369. https://dx.doi.org/10.1007/s40521-017-0140-6
  10. Harvey J., Lax S.J., Lowe A., et al. The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review. Skin Health and Disease 2023;3(5):e268. https://dx.doi.org/10.1002/ski2.268.
  11. Asif A.H., Kaliyadan F., Gite V.V., et al. Standardization of topical preparations for finger-tip unit-Awareness and attitudes among pharmacists and dermatologists and suggestions to improve standardization of topical drug dosing-A two-phase cross-sectional survey. J Cosmet Dermatol. 2022;21(8):3555–3560. https://dx.doi.org/10.1111/jocd.14663
  12. Luk D., Hon K.L.E., Dizon M.V.C., et al. Practical recommendations for the topical treatment of atopic dermatitis in South and East Asia. Dermatol Ther (Heidelb) 2021;11(1):275–291. https://dx.doi.org/10.1007/s13555-020-00467-8
  13. Stalder J.F., Aubert H., Anthoine E., et al. Topical corticosteroid phobia in atopic dermatitis: international feasibility study of the TOPICOP score. Allergy. 2017;72(11):1713–1719. https://dx.doi.org/10.1111/all.13189
  14. Broeders J.A., Ahmed Ali U., Fischer G. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol. 2016;75(2):410–419. https://dx.doi.org/10.1016/j.jaad.2016.02.1228
  15. Lax S.J., Van Vogt E., Candy B., et al. Topical anti-inflammatory treatments for eczema: a Cochrane systematic review and network meta-analysis. Clin Exp Allergy. 2024;54(12):960–972. https://dx.doi.org/10.1111/cea.14556
  16. Remitz A., De Pita O., Mota A., et al. Position statement: topical calcineurin inhibitors in atopic dermatitis. JEADV. 2018;32(12):2074–2082. https://dx.doi.org/10.1111/jdv.15272
  17. Luger T., Augustin M., Lambert J., et al. Unmet medical needs in the treatment of atopic dermatitis in infants: an expert consensus on safety and efficacy of pimecrolimus. Pediatr Allergy Immunol. 2021;32(3):414–424. https://dx.doi.org/10.1111/pai.13422
  18. Luger T., Paller A.S., Irvine A.D., et al. Topical therapy of atopic dermatitis with a focus on pimecrolimus. JADV. 2021;35(7):1505–1518. https://dx.doi.org/10.1111/jdv.17272
  19. Sahnia V.N., Baloghb E.A., Strowdb L.C., Feldmanb S.R. The evolving atopic dermatitis management landscape. Expert Opin Pharmacother. 2022;23(4): 517–526. https://dx.doi.org/10.1080/14656566.2021.2016333
  20. Kemény L. The golden ages of inflammatory skin diseases: skyrocketing developments in the therapy of psoriasis and atopic dermatitis. JEADV. 2021;35(11):2239–2240. https://dx.doi.org/10.1111/jdv.17655
  21. Chu C.-Y. Treatments for childhood atopic dermatitis: an update on emerging therapies. Clin Rev Allergy Immunol. 2021;61(2):114–127. https://dx.doi.org/10.1007/s12016-020-08799-1
  22. Chu D.K., Chu A.W.L., Rayner D.G., et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1493–1519. https://dx.doi.org/10.1016/j.jaci.2023.08.030
  23. Chen S.L., Yan J., Wang F.S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat. 2010;21(3):144–156. https://dx.doi.org/10.3109/09546630903401470
  24. Sigurgeirsson B., Boznanski A., Todd G., et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597–606. https://dx.doi.org/10.1542/peds.2014-1990
  25. Cury Martins J., Martins C., Aoki V., et al. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;2015(7):CD009864. doi: 10.1002/14651858.CD009864.pub2
  26. Reda A.M., Elgendi A., Ebraheem A.I, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366–373. https://dx.doi.org/10.1080/09546634.2018.1524823
  27. Schneider L., Hanifin J., Boguniewicz M., et al. Study of the atopic march: development of atopic comorbidities. Pediatr Dermatol. 2016;33(4):388–398. https://dx.doi.org/10.1111/pde.12867
  28. Pena J., Zameza P.A., Pixley J.N., et al. A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis. JACI: In Practice. 2023;11(5):1347–1359. https://dx.doi.org/10.1016/j.jaip.2023.03.022
  29. Asgari M.M., Tsai A.L., Avalos L., et al. Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis. JAMA Dermatology. 2020;156(10):1066–1073. https://dx.doi.org/10.1001/jamadermatol.2020.2240
  30. Paller A.S., Stein Gold L., Soung J., et al. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis. J Am Acad Dermatol. 2021;84(3):632–638. https://dx.doi.org/10.1016/j.jaad.2020.05.135
  31. Devasenapathy N., Chu A., Wong M., et al; Group Aaaai Acaai Joint Task Force on Practice Parameters for Atopic Dermatitis Guideline Development. Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis. Lancet Child Adolescent Health. 2023;7(1):13–25. https://dx.doi.org/10.1016/S2352-4642(22)00283-8
  32. Chu D.K., Schneider L., Asiniwasis R.N., et al. AКtopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132(3):274–312. https://dx.doi.org/10.1016/j.anai.2023.11.009
  33. Williams H.C., Schmitt J., Thomas K.S. The HOME Core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022;149:1899–1911. https://dx.doi.org/10.1016/j.jaci.2022.03.017

Supplementary files

Supplementary Files
Action
1. JATS XML

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).